Wealth Enhancement Advisory Services Boosts Sarepta Therapeutics Holdings

Institutional investor increases stake in biotech company by nearly 144% in Q4

Apr. 2, 2026 at 11:26am

Got story updates? Submit your updates here. ›

Wealth Enhancement Advisory Services LLC, a financial advisory firm, significantly increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter of 2025. The firm added 62,981 shares, bringing its total stake in the biotechnology company to 106,759 shares, or about 0.10% of Sarepta's outstanding stock.

Why it matters

This transaction highlights the continued institutional investor interest in Sarepta Therapeutics, a leading developer of precision genetic medicines for rare neuromuscular diseases. The firm's increased position could signal confidence in Sarepta's pipeline and commercial prospects.

The details

According to a recent SEC filing, Wealth Enhancement Advisory Services acquired the additional 62,981 Sarepta shares in the fourth quarter, representing a 143.9% increase in its holdings. The firm now owns approximately 106,759 shares of the biotechnology company's stock, valued at around $2.41 million as of the most recent filing.

  • Wealth Enhancement Advisory Services filed its Q4 2025 disclosure with the SEC on April 2, 2026.

The players

Wealth Enhancement Advisory Services LLC

A financial advisory firm that manages investments and provides wealth management services.

Sarepta Therapeutics, Inc.

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases.

Got photos? Submit your photos here. ›

The takeaway

Sarepta Therapeutics' ability to attract increased institutional investment, even amid broader market volatility, underscores the company's promising pipeline and the potential of its precision genetic medicine approach to rare diseases.